Delivery Order 36F79719D0247-36C26025F0033
Award Date
10/25/24
Potential Completion Date
10/24/25
Potential Value
$370K
Federal Agency
Veterans Integrated Service Network 20
Awardee
Ucb, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Pittsburgh, PA 15275, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Department of Veterans Affairs (VA) awarded a delivery order contract valued at $65,982.84 to UCB, Inc. for the pharmaceutical drug ZilbrysQ. This delivery order is placed against a larger Blanket Purchase Agreement (BPA) held by UCB, Inc. with the VA National Acquisition Center, which has a total ceiling value of $264,295.45. UCB, Inc. is a global biopharmaceutical company that focuses on neurology and immunology disorders. The contract is a firm fixed-price arrangement with an...
This is a federal contract award from the Department of Veterans Affairs (VA) to Ucb, Inc., a global biopharmaceutical company. The contract is a Delivery Order under the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) with a ceiling value of $92,524.95. The contract will procure the drug ZilbrysQ to treat patients within the VA healthcare system. Ucb, Inc. holds several Blanket Purchase Agreements (BPAs) with the VA worth over $600 million that provide access to a range of...
This is a federal contract award to Actelion Pharmaceuticals US, Inc., a for-profit pharmaceutical manufacturer, by the Department of Veterans Affairs (VA). The contract is a Blanket Purchase Agreement (BPA) awarded against Actelion's existing Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The BPA has a ceiling value of $83.5 million and a one-year period of performance. It covers the procurement of Actelion's specialized medications for treating pulmonary...
The Department of Veterans Affairs (VA) Veterans Health Administration awarded a firm-fixed-price delivery order to Biogen U.S. Corporation, a pharmaceutical manufacturer, for the supply of QALSODY and QALSODY (TOFERSEN) 6.7MG SOLN. This $43,476.60 order was placed against Biogen's Pharmaceuticals and Drugs GSA Schedule contract and will be delivered by June 1, 2024. Biogen also holds a $11.39 million single-award indefinite delivery contract with the VA National Acquisition Center to provide...
This federal contract award, valued at $43,476.60, was issued by the Department of Veterans Affairs (VA) to Biogen U.S. Corporation, a pharmaceutical and biotechnology company. The contract is a firm-fixed-price delivery order placed against Biogen's Pharmaceuticals and Drugs General Services Administration (GSA) Schedule contract. The contract is for the delivery of QALSODY (tofersen), a pharmaceutical product used to treat neurological conditions in veterans. This award does not carry a...
This federal contract award is a Blanket Purchase Agreement (BPA) call for pharmaceutical products issued by the Department of Veterans Affairs (VA) to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer. The contract has a ceiling value of $99,785.07 and a completion date of September 28, 2017. The contract is a firm fixed-price agreement under the VA's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. This contract facilitates the procurement of critical...
This is a firm fixed-price Blanket Purchase Agreement (BPA) call contract awarded by the Department of Veterans Affairs (VA) to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer. The contract, valued at $258,159.26, is for the express procurement of pharmaceutical orders through the VA's National Acquisition Center to support the VA's Pharmacy Service Network 19 (VISN 19). The contract is not set aside for any specific business category. This BPA call is a part of Actelion's...
This is a $351,244.44 firm fixed-price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer. The order is for specialty medication, primarily treatments for pulmonary arterial hypertension, which are critical drugs for VA medical centers and other federal healthcare facilities. The contract is placed against Actelion's $105 million Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs...
This is a federal contract award to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a pharmaceutical manufacturer of biologic therapies. The contract is a delivery order valued at $18,803.91 for the oncology medication BALVERSA 4 MG, awarded by the U.S. Department of Veterans Affairs (VA) through the Veterans Health Administration. The contract is a firm fixed price delivery order with no set-aside designation, issued against the Pharmaceuticals and Drugs Federal Supply...
The U.S. Department of Veterans Affairs (VA) awarded a Delivery Order contract worth $83,998.80 to United Therapeutics Corp, a self-certified small disadvantaged business and manufacturer of pharmaceutical goods. The contract is placed against United Therapeutics' Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) and provides the VA with Tyvaso, an inhaled solution used to treat pulmonary arterial hypertension. This Delivery Order does not have a set-aside...